Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Inclusion Criteria: * Subject is a recipient of a de novo kidney from a living or deceased donor and has biopsy-proven, primary FSGS (pFSGS) as a cause of end stage renal disease (ESRD) in the subject's native kidneys (initial diagnosing biopsy report is required). A subject who has biopsy-proven pFSGS as a cause of ESRD, and the subject's most current graft failure(s) is due to the recurrence of FSGS, is eligible. * Subject is anticipated to receive first oral dose of tacrolimus within 48 hours of transplant procedure. * Subject must be willing and able to comply with the study requirements including prohibited concomitant medication restrictions. * Subject agrees not to participate in another interventional study while on treatment. Exclusion Criteria: * Subject has Induction therapy, other than study-assigned basiliximab, planned as part of initial immunosuppressive regimen. * Subject has a diagnosis of secondary FSGS (familial, virus associated, medication, etc.) or a defined genetic cause of FSGS. * Subject has previously received any organ transplant including a kidney and the most current graft failure(s) is not due to the recurrence of FSGS. * Subject will receive a kidney as part of a multi-organ transplant. * Subject will receive a dual kidney transplant from a deceased donor. * Subject will receive a kidney with an anticipated cold ischemia time (CIT) of \> 30 hours. * Subject will receive a kidney that meets BOTH Extended Criteria Donor (ECD) and Donation after…